InMed Updates Progress of its Epidermolysis Bullosa Program
– Momentum Public Relations – May 18th, 2016
InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies is pleased to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that has been specifically designed to: (i) modify the underlying cause of the disease in patients with epidermolysis bullosa simplex (EBS, the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed is now pleased to report that INM-750 has demonstrated positive pain relieving effects in animal models. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “I am very excited with these results as pain is a serious complication in EB and this animal data shows that INM-750 reduces both acute and chronic pain. Significant data has been previously generated and reported to demonstrate the diverse properties of INM-750 in wound healing, skin regeneration, anti-inflammation and its antibacterial effects. Together with pain, these disease hallmarks are key therapeutic targets for the effective treatment of EB as well as several other dermatological conditions.”
A summary of the pre-clinical results on INM-750, a non-THC cannabinoid based composition, is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in severe skin fragility that can range from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.